January 2022

breaking news

Treatment with interferon-λ confers protection from SARS-CoV-2 variants – Beta and Omicron

In a recent paper, Chong, et al., investigated the effect of IFN-λ on SARS-CoV-2 infection in mice. They found that IFN-λ conferred protection against the SARS-CoV-2 B.1.351 (Beta variant) and…

ChelekaJanuary 31, 2022

breaking news

Th17 and Multiple Sclerosis (MS)

In a recent study, Wilson, et al., have described how Th17 cell promote the onset of certain autoimmune diseases such as multiple sclerosis (MS). The researchers have discovered a mechanism…

ChelekaJanuary 28, 2022

breaking news

A potential end to peanut allergies?

In a recent paper, results published in The Lancet from a clinical trial has reported that through the administration of peanut oral immunotherapy in children, ages 1-3, who are extremely…

ChelekaJanuary 27, 2022

breaking news

Why is SARS-CoV-2 Omicron less severe than Delta?

A new study by Bojkova, et al., reported on the SARS-CoV-2 Omicron variant and why it is less efficient than the Delta variant at inhibiting/blocking the host cellular defense mechanism…

ChelekaJanuary 25, 2022

breaking news

A new target for TB treatment with great potential

Beites, et al., have investigated the function and role of an Mtb enzyme that has never been studied in detail. They reported that the enzyme is essential for Mtb's breakdown…

ChelekaJanuary 23, 2022

breaking news

Formation of tertiary lymphoid tissue: fighting chronic inflammation

A recent article published in Kidney International highlights novel findings concerning Tertiary lymphoid tissues (TLTs), which are ectopic lymphoid tissues formed due to chronic inflammatory microenvironment which functions as a…

ChelekaJanuary 19, 2022

breaking news

Our natural defence to skin cancer – new insights

Avolio, et al., reported that the protein CSDE1 coordinates a complex chain of events that enable senescence in skin cells, significantly slowing down their function without causing death. The result,…

ChelekaJanuary 17, 2022

breaking news

Can we use cannabinoids to block SARS-CoV-2 viral entry?

Van Breemen, et al., reported on a pair of cannabinoid acids, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), that can bind to the SARS-CoV-2 spike protein, inhibiting/blocking a crucial element…

ChelekaJanuary 13, 2022

breaking news

Toothpaste – a trigger for gut inflammation

A recent study using murine models has reported that an antimicrobial found in toothpaste, triclosan (TCS), in addition to other toys and products, can lead to or trigger gut inflammation.…

ChelekaJanuary 11, 2022

breaking news

How do immune cells invade tissue?

In a recent discovery that may aid researchers in identifying new targets for cancer treatment, Belyaeva, et al., 2021 have discovered how immune cells protect themselves when they enter and…

ChelekaJanuary 9, 2022

breaking news

T-cell response to SARS-CoV-2 Omicron

In a recent observational study, De Marco, et al., investigated mechanisms of how the Omicron variant of SARS-CoV-2 (B.1.1.529) evades cellular immunity. An interesting paper and extremely relevant during these…

ChelekaJanuary 5, 2022

Treatment with interferon-λ confers protection from SARS-CoV-2 variants – Beta and Omicron

Th17 and Multiple Sclerosis (MS)

A potential end to peanut allergies?

Why is SARS-CoV-2 Omicron less severe than Delta?

A new target for TB treatment with great potential

Formation of tertiary lymphoid tissue: fighting chronic inflammation

Our natural defence to skin cancer – new insights

Can we use cannabinoids to block SARS-CoV-2 viral entry?

Toothpaste – a trigger for gut inflammation

How do immune cells invade tissue?

T-cell response to SARS-CoV-2 Omicron

Advancing Global Online Immunology Education for 20 years

Join our Newsletter

Advancing Global Immunology Education